Albert P. Parker's Insider Trades & SAST Disclosures
Albert P. Parker's most recent trade in Zynerba Pharmaceuticals Inc was a trade of 3,173 Common Stock done at an average price of $0.5 . Disclosure was reported to the exchange on Feb. 15, 2023.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Albert P. Parker.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Zynerba Pharmaceuticals Inc | Albert P. Parker | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 0.54 per share. | 15 Feb 2023 | 3,173 | 227,018 (0%) | 0% | 0.5 | 1,719 | Common Stock |
| Zynerba Pharmaceuticals Inc | Albert P. Parker | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2023 | 18,864 | 235,654 (1%) | 0% | - | Common Stock | |
| Zynerba Pharmaceuticals Inc | Albert P. Parker | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.60 per share. | 07 Feb 2023 | 5,463 | 230,191 (0%) | 0% | 0.6 | 3,259 | Common Stock |
| Zynerba Pharmaceuticals Inc | Albert P. Parker | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 17,631 | 222,631 (0%) | 0% | - | Common Stock | |
| Zynerba Pharmaceuticals Inc | Albert P. Parker | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.60 per share. | 31 Jan 2023 | 5,841 | 216,790 (0%) | 0% | 0.6 | 3,477 | Common Stock |
| Zynerba Pharmaceuticals Inc | Albert P. Parker | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2023 | 170,000 | 205,000 (0%) | 0% | 0 | Common Stock | |
| Zynerba Pharmaceuticals Inc | Albert P. Parker | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 200,000 | 200,000 | - | - | Stock Option (right to buy) | |
| Zynerba Pharmaceuticals Inc | Albert P. Parker | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 35,000 | 35,000 (0%) | 0% | 0 | Common Stock | |
| Oncocyte Corporation | Albert P. Parker | COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2020 | 5,586 | 10,586 (0%) | 0% | - | Common Stock | |
| Oncocyte Corporation | Albert P. Parker | Chief Operating Officer | Purchase of securities on an exchange or from another person at price $ 1.33 per share. | 03 Aug 2020 | 5,000 | 5,000 (0%) | 0% | 1.3 | 6,648 | Common Stock, no par value |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges